2018 A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
- Cancer Research and Treatment, published online September 7, 2018
2018 Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- N Engl J Med 2018 Sep 25; DOI: 10.1056/NEJMoa1809697
2018 Clinical activity of Pan-HER inhibitors against HER2 mutant lung adenocarcinoma
- Clinical Lung Cancer, 2018
2018 Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea
-Lung Cancer 119, 36-41, 2018
2018 Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- The Lancet Oncology 19 (4), 521-536, 2018
2017 Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
- Journal of Korean medical science 33 (1), 2017
2017 Durvalumab after Chemoradiotherapy in Stage III Non?Small-Cell Lung Cancer
- N Engl J Med 2017; 377:1919-1929
2017 A Randomized Phase III Study of Docetaxel plus Cisplatin versus Pemetrexed plus Cisplatin as First-line Treatment for Non-squamous Non-small Cell Lung Cancer: A TRAIL Trial
- Clin Lung Cancer. 2017 Jan 11. pii: S1525-7304(17)30002-5. doi: 10.1016/j.cllc.2017.01.002.
2016 A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study
- Clin Lung Cancer. 2016 May;17(3):232-236
2012 Proportion and Characteristics of Transient Nodules in a Retrospective Analysis of Pulmonary Nodules
- Thoracic Cancer 2012 Aug 3(3):224-228.
2012 Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m2 for the treatment of non-small cell lung cancer
- Experimental and Therapeutic Medicine 2012 Aug;4(2):317-322
2012 Retreatment of Gefitinib in Patients with Non-Small-Cell Lung Cancer Who Previously Controlled to Gefitinib; A Single-Arm, Open-Label, Phase II Study.
- Lung Cancer. 2012 Jul;77(1):121-7.
2011 Response to Gemcitabine-Platinum Chemotherapy by Single Nucleotide Polymorphisms of RRM1 and ERCC1 Genes in Patients with Non-Small Cell Lung Cancer
- Thoracic cancer, 2011 online publication ahead of print, DOI: 10.1111/j.1759-7714.2011.00082.x
2011 Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with ERCC1 expression and genotype
- Respirology. 2011 online publication ahead of print, DOI: 10.1111/j.1440-1843.2011.02060.x
2009 Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: A Korean Lung Cancer Registry Study.
- Lung Cancer. 64 (2009) 232-237
2008 Efficacy of Gemcitabine in Patients with Non Small Cell Lung Cancer According to Promoter Polymorphisms of the Ribonucleotide Reductase M1 Gene
- Clin Cancer Res. 2008;14(10) 3083
2005 Predictors of the Response to Gefitinib in Refractory Non-Small Cell Lung Cancer
- Clin Cancer Res 2005 Mar;11(6): 2244-2251
그외 다수